EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina

Alma Badnjević-Čengić, Ranko Škrbić, Adna Softić iD, Tamer Bego, Neven Meseldžić, Nataša Stojaković, Neira Crnčević, Sara Deumić iD, Damira Kadić, Armin Mooranian, Hani Al-Salami, Momir Mikov

Technology and Health Care · 2026-09 · 34 (5) · 641-652

DOI: 10.1177/09287329261438698 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Technology and Health Care, online erschienen am 25.04.2026. Verfasst von Alma Badnjević-Čengić und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Diabetes, Internal Medicine Department with Hemodialysis, Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Probiotics, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent research highlights the pivotal role of gut microbiota and bile acids as modulators of metabolic homeostasis in type 2 diabetes (T2D). The concomitant use of probiotics and ursodeoxycholic acid (UDCA) may potentiate glycemic and lipid control via complementary mechanisms.

Objective

To evaluate the metabolic effects of probiotic supplementation and its combination with UDCA in metformin-treated T2D patients.

Methods

In this monocentric, prospective, randomized, double-blind, controlled trial, 90 patients with T2D on metformin therapy were randomized into three groups: metformin-only (MG), metformin plus probiotic (MPG), and metformin plus probiotic plus UDCA (MPUG). The intervention lasted 4 weeks. Primary outcomes included changes in fasting glucose, postprandial glucose and HbA1c. Secondary outcomes included lipid profile, C-reactive protein (CRP), and fecal levels of probiotics and UDCA. Two visits were conducted during the study - at the beginning and at the end. Visits involved patient interviews, clinical data collection, anthropometric measurements, blood biochemical analyses, and stool sample analysis for the presence of probiotic culture and UDCA concentrations.

Results

After 4 weeks, the MPUG group showed a significant reduction in fasting glucose (−1.7 mmol/L; 95% CI: −2.2 to −1.2), postprandial glucose (−1.3 mmol/L; 95% CI: −1.8 to −0.7), and HbA1c (−0.49%; 95% CI: −0.66 to −0.31) compared to the MG group. Total cholesterol and LDL cholesterol were also significantly reduced, while HDL increased. The concentration of Lactobacillus rhamnosus GG was highest in the MPUG group. No serious adverse events were reported.

Conclusion

Co-administration of probiotics and UDCA for four weeks in metformin-treated T2D patients significantly improves short-term glycemic control and lipid profiles. These promising results warrant validation in larger, longer-term clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2ProbioticsHypoglycemic AgentsUrsodeoxycholic AcidHumansFemaleBlood GlucoseDouble-Blind MethodGlycated HemoglobinMaleProspective StudiesMiddle AgedBosnia and HerzegovinaLipidsC-Reactive ProteinDrug Therapy, CombinationAged

Stichwörter der Autor:innen

T2DUDCAmetforminprobioticsrandomized trial

Substanzen

MetforminBlood GlucoseHypoglycemic AgentsGlycated HemoglobinUrsodeoxycholic AcidLipidsC-Reactive Protein

Autor:innen und Institutionen

  • Department of Endocrinology and Diabetes, Internal Medicine Department with Hemodialysis, Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina.
  • Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
  • Department of Pathologic Physiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Verlab Research Institute for Biomedical Engineering, Medical Devices and Artificial Intelligence, Sarajevo, Bosnia and Herzegovina.
  • Department of Medical Biotechnologies, University of Siena, Siena, Italy.
  • Department of Pharmaceutical Biochemistry and Laboratory Diagnostics, Faculty of Pharmacy, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

ORCID-Profile: Adna Softić, Sara Deumić

Zitieren

APA

Badnjević-Čengić, A., Škrbić, R., Softić, A., Bego, T., Meseldžić, N., Stojaković, N., Crnčević, N., Deumić, S., Kadić, D., Mooranian, A., Al-Salami, H., & Mikov, M. (2026). Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina. Technology and Health Care, 34(5), 641-652. https://doi.org/10.1177/09287329261438698

Vancouver

Badnjević-Čengić A, Škrbić R, Softić A, Bego T, Meseldžić N, Stojaković N, et al. Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina. Technology and Health Care. 2026;34(5):641-652. doi:10.1177/09287329261438698

BibTeX
@article{Badnjeviengi2026,
  author = {Badnjević-Čengić, Alma and Škrbić, Ranko and Softić, Adna and Bego, Tamer and Meseldžić, Neven and Stojaković, Nataša and Crnčević, Neira and Deumić, Sara and Kadić, Damira and Mooranian, Armin and Al-Salami, Hani and Mikov, Momir},
  title = {Effects of UDCA and probiotics on metabolic outcomes in type 2 diabetes patients on metformin: A randomized trial in Bosnia and Herzegovina},
  journal = {Technology and Health Care},
  year = {2026},
  volume = {34},
  number = {5},
  pages = {641--652},
  doi = {10.1177/09287329261438698}
}
Kostenlos starten →